Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEG-LYTE vs GOLYTELY
Head-to-head clinical comparison of therapeutic indices and safety profiles.
PEG-LYTE is an osmotic laxative that induces diarrhea by retaining water in the colon through the non-absorbable polyethylene glycol (PEG) and electrolytes, which prevent dehydration and electrolyte imbalance during bowel cleansing.
Polyethylene glycol 3350 is an osmotic laxative that induces diarrhea by retaining water in the bowel lumen through osmotic activity. Electrolytes (sodium sulfate, potassium chloride, sodium bicarbonate) prevent significant electrolyte absorption or loss.
Bowel cleansing prior to colonoscopy,Bowel cleansing prior to barium enema X-ray examination
Bowel cleansing prior to colonoscopy,Bowel cleansing prior to barium enema
4 liters orally as a single dose or in divided doses for colonoscopy preparation.
240 m L (oral) every 10 minutes until 4 L consumed or rectal effluent is clear; typically 4 L total over 3-4 hours.
Not applicable; PEG-3350 is minimally absorbed (<0.06%), thus systemic half-life is not clinically relevant. Local gut transit time ~1-2 hours.
Not applicable (PEG 3350 is not significantly absorbed; effective half-life in GI tract is approximately 2-4 hours for colonic clearance).
Polyethylene glycol (PEG) is not metabolized and is excreted unchanged in feces. The electrolytes (sodium, potassium, bicarbonate, chloride) are absorbed and metabolized according to normal physiological pathways.
Contraindicated in patients with GFR < 30 m L/min/1.73 m² due to risk of electrolyte abnormalities and fluid overload. For GFR 30-60 m L/min/1.73 m², use with caution and monitor electrolytes.
No dose adjustment required for renal impairment; use with caution in severe renal disease due to potential fluid/electrolyte imbalance.
None
No known teratogenic risk. Insufficient data for first trimester; minimal systemic absorption makes fetal exposure unlikely. No evidence of fetal harm during second and third trimesters.
Golytely (polyethylene glycol 3350) is not systemically absorbed, thus no direct fetal exposure. Based on lack of absorption and animal studies, risk is minimal. No adequate human data, but FDA category C. Use during pregnancy only if clearly needed.
PEG-LYTE (polyethylene glycol 3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalance; monitor renal function in elderly or patients with kidney disease. Do not add other ingredients; refrigerate after reconstitution to improve palatability. Advise splitting doses (split regimen) for better tolerance and efficacy. Contraindicated in ileus, bowel obstruction, perforation, toxic colitis, and severe renal impairment.
GOLYTELY (polyethylene glycol 3350 with electrolytes) is an osmotic laxative used for bowel cleansing prior to colonoscopy. Ensure adequate hydration before, during, and after administration. Administer in divided doses: half the evening before and half the morning of the procedure. Monitor for nausea, vomiting, or aspiration risk in elderly or debilitated patients. Discontinue if severe bloating or abdominal pain occurs.
No interactions on record
No interactions on record
PEG-LYTE and GOLYTELY are distinct pharmacological agents. PEG-LYTE belongs to the Osmotic Laxative class and is primarily used for Bowel cleansing prior to colonoscopyBowel cleansing prior to barium enema X-ray examination. GOLYTELY belongs to the Osmotic Laxative class and is primarily used for Bowel cleansing prior to colonoscopyBowel cleansing prior to barium enema. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. PEG-LYTE carries a safety status of Category C, whereas GOLYTELY safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Not metabolized; excreted unchanged in feces.
Primarily fecal (98-99%) as unchanged polyethylene glycol (PEG) 3350; negligible renal excretion (<0.2%). Electrolytes (sodium, potassium, bicarbonate) are partially absorbed and excreted renally.
Primarily fecal elimination of unabsorbed polyethylene glycol 3350. Minimal systemic absorption (<0.06%), less than 0.06% recovered in urine as intact PEG 3350; electrocytes and sulfate (from sodium sulfate) are renally excreted.
Negligible (<1%); PEG-3350 does not bind to plasma proteins.
Not applicable (PEG 3350 is a large polymer with negligible systemic absorption; no protein binding data).
Not applicable due to negligible absorption. For absorbed fraction, estimated Vd ~0.3 L/kg (based on PEG distribution to extracellular fluid).
Not applicable (PEG 3350 remains largely in GI tract; Vd not clinically relevant due to minimal absorption).
Oral: <0.06% (systemic absorption of PEG-3350 is minimal). Electrolytes are absorbed variably.
Oral: <0.06% (systemic bioavailability of PEG 3350 is negligible).
No specific dose adjustment required for Child-Pugh A or B. For Child-Pugh C, use with caution due to ascites risk.
No dose adjustment recommended for hepatic impairment; use caution in severe hepatic disease.
Weight-based dosing: 25-40 m L/kg per dose, up to a maximum of 4 liters total, for colonoscopy preparation. Dose should be adjusted based on clinical response and tolerability.
25-40 m L/kg/hour (oral) until clear rectal effluent; maximum 4 L; not recommended for children <6 months.
Initiate at lower doses (e.g., 2 liters total) with slower administration, monitor for dehydration and electrolyte imbalances, and consider split-dose regimens.
Use with caution; monitor fluid and electrolyte status closely due to increased risk of aspiration, dehydration, and renal impairment.
No black box warning.
Risk of aspiration and regurgitation (especially in patients with impaired gag reflex), serious fluid and electrolyte disturbances (especially in patients with renal impairment, electrolyte abnormalities, or those taking diuretics or other medications that affect electrolytes), risk of cardiac arrhythmias due to electrolyte shifts, potential for mucosal ulcerations or ischemic colitis, and use with caution in patients with severe ulcerative colitis or toxic megacolon.
Gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon, ileus, hypersensitivity to any component of the product.
Avoid solid foods during bowel prep; only consume clear liquids (water, clear broth, gelatin, clear fruit juices without pulp). Avoid alcohol and dairy products. No food interactions with the drug itself, but dietary restrictions are critical for efficacy and safety.
Avoid solid food for at least 2 hours before starting GOLYTELY. Only clear liquids are recommended during bowel preparation. Avoid dairy products, alcoholic beverages, and red or purple liquids. Do not consume any food or drink containing pulp or seeds.
PEG-LYTE (polyethylene glycol 3350 with electrolytes) is minimally absorbed systemically and not expected to be excreted into breast milk. M/P ratio not applicable due to negligible plasma levels.
Not absorbed systemically, thus no excretion into breast milk expected. Considered compatible with breastfeeding. M/P ratio not applicable due to lack of absorption.
No dose adjustment required. Pharmacokinetics unchanged due to negligible absorption. Use standard dosing as clinically indicated.
No dose adjustment required; pharmacokinetics unchanged due to lack of absorption. Use standard dose for bowel cleansing.
Take exactly as prescribed; do not add extra flavorings or sweeteners.,Drink plenty of clear liquids during the bowel prep to stay hydrated.,Refrigerate the solution to improve taste; do not freeze.,Expect frequent, watery stools; avoid strenuous activities.,Stop taking other oral medications within 1 hour before starting the prep.,Call your doctor if you experience severe vomiting, dizziness, or fainting.
Drink the solution as directed. Do not add any other ingredients.,Do not eat solid food for at least 2 hours before starting the solution.,Stay near a bathroom as bowel movements will begin within 1-2 hours.,If you experience severe bloating, nausea, or vomiting, stop and rest, then resume if tolerated.,Complete all doses as prescribed for effective colon cleansing.,Common side effects include nausea, bloating, and cramping.